Skip to main content

Advertisement

SpringerLink
Log in

2017 FDA drug approvals

  • News and Analysis
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

A Corrigendum to this article was published on 01 February 2018

This article has been updated

The FDA approved 46 new drugs last year, the highest total in more than two decades.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Novel FDA approvals since 1993.
Figure 2: 2017's potential blockbuster approvals.
Figure 3: CDER approval trends over time.
Figure 4: CDER approvals by therapeutic area in 2017.

Change history

  • 01 February 2018

    Semaglutide is the sixth GLP1 agonist to receive FDA approval, not the fifth as originally noted. This correction has been made in the print and online versions.

Authors
  1. Asher Mullard
    View author publications

    You can also search for this author in PubMed Google Scholar

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mullard, A. 2017 FDA drug approvals. Nat Rev Drug Discov 17, 81–85 (2018). https://doi.org/10.1038/nrd.2018.4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2018.4

  • Springer Nature Limited

This article is cited by

Search

Navigation